Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extracellular Vesicle Infusion for Age-Related Impaired Glucose Tolerance
NCT06495437Not yet recruiting
- Sponsor
- Beautech Healthcare
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Lipid-based Nanoparticles, Cell Therapies
01
Overview
Open-label, single-arm trial of extracellular vesicles derived from Wharton's jelly mesenchymal stem cells in impaired glucose tolerance (IGT), sponsored by Beautech Healthcare. Primary endpoint: Safety Evaluation. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
extracellular vesicles derived from Wharton's jelly mesenchymal stem cells
03
Conditions
impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT06495437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495437.